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Abstract 
Background: Toxoplasmosis is a disease caused by the intracellular protozoan parasite, 
Toxoplasma gondii which infects up to one third of the world human population.  
Toxoplasmosis in neonates and immunocompromised patients can lead to severe disease and 
death.   
Objective:  1) To investigate the prevalence and risk factors for T. gondii  infection in 
Iceland, Sweden and Estonia. 2) To test the hypothesis that the encysted state of  T. gondii  
infection causes systemic inflammation. 
Material and methods: Blood samples were collected from 1277 randomly selected subjects. 
The presence of  T .gondii IgG antibodies was determined by an ELISA method and levels of 
Hs-CRP by immunoturbidimetric assay. 
Results: The prevalence of  T. gondii  antibodies was 54,9% in Tartu, 23% in Uppsala and 
9,8% in Reykjavik (p<0.0001). The risk of positive T. gondii antibodies increased with the 
number of siblings and with age in Sweden. T. gondii infection was associated with asthma 
related symptoms and increased Hs-CRP (p=0.02). No association was found with IgE-
sensitisation and lung function. 
Conclusion: The risk factors for T. gondii infection suggested that soil exposure was one of 
the  mechanisms in all three countries and meat associated infection route is a risk in Sweden. 
Hs-CRP indicates a role of T, gondii in systemic inflammation and asthma. 
 
 
 
 2
 3
 
 
 
Key words 
Toxoplasma gondii/epidemiology  
Toxoplasma gondii /Asthma  
Toxoplasma gondii /C reactive protein 
High sensitivity C-Reactive Protein (HsCRP) 
Hygiene 
Risk Factors 
 
Cats 
Cookery 
Humans 
Meat 
Pregnancy 
 3
 4
Introduction. 
Toxoplasmosis is a disease caused by the intracellular protozoan parasite, Toxoplasma gondii. 
Toxoplasmosis is one of the more common parasitic zoonoses world-wide and it has been 
estimated that up to one third of the world human population has been exposed to the parasite 
(1). Eighty to 90 percent of acute T. gondii infections in immunocompetent hosts are 
asymptomatic (2) but latent asymptomatic infection can persist for the life of the host. In 
immunosuppressed patients, especially patients with the acquired immunodeficiency 
syndrome (AIDS) the parasite can reactivate and cause disease. Toxoplasmosis was found to 
be the most frequent and severe neurologic infection among persons with AIDS in the United 
States (3). Newly acquired T. gondii infection in a pregnant woman can be transmitted to the 
fetus and may cause mental retardation, blindness, epilepsy, and death. Over the past 3 
decades, the incidence of prenatal infection with T. gondii has been estimated to vary from 1 
to 100 per 10. 000 births in different countries (1).  
Felines of all types are the only animals in which T. gondii can complete its reproductive 
cycle (1, 2). Following feline ingestion of any of the forms of  T. gondii, the parasite infects 
the gut epithelial cells and reproduces. The feline then excretes infectious oocysts in feces for 
about two weeks (4).  Oocysts become infective one to five days after excretion, are spread by 
surface water, and can survive for more than a year (4).  If non-felines, including humans, 
ingest T. gondii oocysts, the organisms invade intestinal epithelium and disseminate 
throughout the body. They then encyst and can lie dormant in any nucleated cells within 
tissues for the life of the host.  
Seroprevalence estimates vary greatly among different countries, among different 
geographical areas within one country, and among different ethnic groups living in the same 
area. Over the past 3 decades antibodies to T. gondii have been detected in from 0 to 100% of 
individuals in various adult human populations (1). A prevalence of 100% has been reported 
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from Saudi Arabia (5), 71% in French women (6), 22,5% in United States (7), 11% in 
Norway (8) and decreasing prevalence has been reported in Swedish women, 34% in 1969 
and 18% in 1987 (9). Regional variations have been attributed to climate (8) cultural 
differences in the amount and type of raw meat consumed and the variable consumption of 
meat from animals farmed indoors and frozen meat. 
 
Ingestion of undercooked meats is responsible for the majority of toxoplasmosis cases in 
France (10)  and in United States undercooked meats accounts for half of the cases (11). In six 
European countries eating undercooked, raw or cured meat contributed to between 30% and 
63% of infections, with soil contact contributing to up to 17% of infections (12).  
However, in most underdeveloped countries infection is more likely due to environmental 
exposure since meats are usually not eaten undercooked. T. gondii is also of importance in 
veterinary disease were it is a common cause of abortion and mortality in sheep and goats 
throughout the world (1). 
 
New aspects of possible health consequences of  T. gondii infection have been suggested in 
recent years. The hygiene hypothesis proposes that changes in the environment due to 
improved hygiene and fewer childhood infections has modulated immune responses away 
from the Th1 cellular responses and toward Th2 responses that favor atopy and allergies (13) 
(14).   T. gondii and other food born infections have been part of the human biota throughout 
human developement and its disappearance may have contributed towards modulated immune 
responses. Furthermore, little attention has been paid to possible effects of  encysted state of  
T. gondii infection on general health such as lung function or systemic inflammation. C-
reactive protein (CRP) is an inflammatory marker known to be a risk factor for cardiovascular 
disease (15). Measurement of  CRP could give an indication of possible interaction of T. 
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gondii with the immune/complement system with potential cardiovascular or systemic 
implications. 
The present study is based on data that were acumulated in The European Community 
Respiratory Health Survey (ECRHS) (16) and contains extensive information on atopy, 
asthma and allergy related pulmonary symptoms and lung function. Serum samples are also 
availible. The present study works with data from Sweden, Estonia and Iceland. The ECRHS 
database makes it possible to test several hypothesis about the interaction of infectious agents,  
atopy and lung related allergic symptoms and the effect on inflammatory parameters. The 
main objectives of the present study were as follows. 1) To document the present serological 
prevalence of T. gondii in Sweden, Estonia and Iceland and attempt to elucidate the risk 
factors for infection. 2) To explore the hypothesis of  involvement of T. gondii with atopy and 
allergy related lung symptoms. 3) To assess possible effects of T. gondii infection on lung 
function and systemic imflammation. 
 
Material and Methods: 
Study sites and population  
The European Community Respiratory Health Survey I (ECRHS I) was a project which was 
embarked on to study geographical difference in the incidence of asthma and atopy and theirs 
risk factors in a young adult population. Individuals aged 20-44 years were randomly selected 
during the period 1990-94, from the population of 22 nations and 48 study sites. Each 
participant was sent a brief questionnaire (Stage 1) and from those who responded, a random 
sample was selected to undergo a more detailed clinical examination (Stage 2). In addition a 
“symptomatic sample”, reporting symptoms of waking with shortness of breath, asthma 
attacks or using asthma medication in stage 1 were also studied.(17) 
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Our study populations comprises all those living in Reykjavik, Uppsala and Tartu who 
participated in ECRHS I (n=2033) and where invited for a repeated study in the years 1999-
2001 (ECRHS II) (18). The median length of follow up was 8.4 years. Blood samples for 
determination of T. gondi status was collected from 1277 subjects (Reykjavik 503, Uppsala 
492, Tartu 282), 606 men and 657 women. Of these 1016 subjects (440 in Reykjavik, 361 in 
Uppsala and 215 in Tartu) were from the random sample and 261 from the symptomatic 
sample.  
The appropriate Ethics Committees approval was obtained in all countries.  
 
Serologic methods 
The presence of  T. gondii IgG antibodies was determined by an ELISA method using 
microtitre plates coated with inactivated T. gondii antigens. For calibration we used T. gondii 
IgG standards calibrated in accordance with the 3rd International Standard of the WHO. All 
reagents were obtained from Novatec Immundiagnostica GmbH, Dietzenbach, Germany. 
Serum samples with titers >35 IU/ml  were classified as positive while equivocal samples 
with titers between 030 – 35 IU/ml and samples with titers 30 IU/ml were classified as 
negative. The diagnostic sensitivity and the specificity of the T. gondii IgG ELISA method 
has been shown to be 96,8% and 100%, respectively (17). 
Questionnaire 
The subjects underwent a structured interview, which included detailed information on 
respiratory symptoms and diagnoses, smoking history, occupation and early life exposure. 
“Asthma” was defined as having physician-diagnosed asthma and having had asthma- related 
symptoms or attacks of asthma in the preceding 12 months (19) From the questionnaire the 
subjects were divided into three smoking history categories: never-smokers, ex-smokers and 
current smokers. The following early life exposure variables were included: hospitalizations 
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before the age of five for lung disease, age when attending day care, bedroom sharing with 
other children before the age of five, pets during childhood and rural versus urban living as a 
child when under the age of five (Table 4). 
Socio-economic status was defined from information on the subjects occupation provided 
during ECRHS I according to the United Kingdom social classification. Using this 
classification the subjects were divided into: (a) professional and semi-professionals, (b) 
skilled non-manual worker, (c) skilled manual worker and (d) unskilled manual workers (e) 
un-defined.  
Body mass index 
Body mass index (BMI) was calculated as weight in kilograms divided by the square of height 
in meters.  
Allergy testing 
Total and specific serum IgE was determined using the Pharmacia CAP System (Pharmacia 
Diagnostics, Uppsala, Sweden). In all centres specific IgE was measured against 
Dermatophagoides pteronyssinus, timothy grass, cat and Cladosporium herbarum. Detection 
of specific IgE (≥0·35 kU/L) was used as the definition of sensitisation. Atopy was defined as 
being sensitised to any of the above allergens. 
 
Systemic inflammation 
High sensitivity C-Reactive Protein (HsCRP) concentrations were measured on a Hitachi 911 
analyzer using a commercially available latex-enhanced immunoturbidimetric assay from 
Roche. The lower detection limit of the assay is 0.1 mg/l. The between-day coefficient of 
variation was 1.1% at a concentration of  3.73 mg/l and 1.9 % at a concentration of 0.68 mg/l. 
Spirometry 
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The maximum forced expiratory volume in one second (FEV1) and maximum forced vital 
capacity (FVC) of up to five technically acceptable blows were determined, and also whether 
FEV1 and FVC each met the American Thoracic Society (ATS) criterion for reproducibility. 
Description of socio-economic development 
The United Nations Human Development Report (20) classifies 178 nations into human 
development categories based on composite Human Development Index (HDI) which ranges 
from 0 to 1. All countries included in the HDI are classified into three clusters by achievement 
in human development: high human development (with an HDI of 0.800 or above), medium 
human development (HDI of 0.500–0.799) and low human development (HDI of less than 
0.500). In the year 2003 Iceland was in 2nd world rank, Sweden 6th and Estonia 38th with HDI 
index of  0,956, 0,949 and 0,853 respectively, all countries in the high development category. 
In the year 1975 Iceland and Sweden had a HDI of 0,863 and 0,864 respectively but the first 
report for Estonia is from 1990 when HDI was 0,814 but in1995 the HDI was 0,795 or in the 
medium category. 
Statistics 
The statistical analysis was performed using Stata 8.0 (Stata Corporation, College Station, 
Texas). Chi squared test and test for trend using unadjusted logistic regression was used when 
comparing differences in T. gondii status between centres, gender and age groups. Multiple 
logistic regression was used to calculate adjusted odds ratios (OR) for the different 
determinants for T. gondii status. Multiple linear regression was used to study associations 
between T. gondii status, lung function and HsCRP. In these analyses adjustments were made 
for age, sex, smoking, BMI and centre and for the spirometric values also for height. The 
adjusted OR was analysed on pooled data from all three centres adjusting for centre. Analyses 
of association between T. gondii status and respiratory health and allergy were performed 
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using both the random and symptomatic sample (n=1277). All other analyses were performed 
on the random sample (n=1016). 
Results 
The data is from 1016 subjects (random sample) (488 men and 528 women), mean age 
41.9+7.3 (range 28-54) years randomly sampled from the population of Reykjavik (n=440), 
Uppsala (n=361) and Tartu (n=215).  The original sample was 1046 but serum samples were 
not available from 30 subjects.  
The number of subjects with a positive serology for T. gondii was 244 (24.0%). The 
prevalence of T. gondii antibodies was highest in Tartu and lowest in Reykjavik (Table 1). 
The prevalence of T. gondii increased significantly by age in Uppsala (p=0.004) but no 
significant age trend was found in the other two centres. The prevalence of T. gondii was 
significantly higher in women than in men in Tartu (68.6 vs. 48.4%, p=0.003) while no 
significant sex difference was found in the other centres.  
Age T. gondii IgG antibodies 
 Reykjavik Uppsala Tartu 
<35 9.3 11.4 58.7 
35-39 9.3 20.0 42.6 
40-44 5.6 28.2 56.8 
45-49 18.3 25.3 57.1 
>50 7.8 30.8 64.3 
28-54 9.8 23.0 54.9 
Table 1 The prevalence of IgG antibodies to T. gondii by age and centre (%). 
 
No significant associations were found between BMI , socio-economic status or smoking 
history and the prevalence of T. gondii in any centre. T. gondii was not significantly 
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associated with age, female gender and ever-smoking when combining data from all centres 
(Table 2). No association was found between having IgG antibodies gainst T. gondii and 
height. 
Early life exposure and the prevalence of  T. gondii 
The following early life variables were assessed: dog, cat and birds during childhood, day 
care before the age of 3 years, hospitalisation because a respiratory infection before the age of 
5 years, mothers age, educational level (age when completing full time education), number of 
siblings and rural vs. urban upbringing. The risk of T. gondii increased with the age of the 
mothers when born in Tartu and in participants that had been in day care before the age of 3 
years in Reykjavik. In the combined model the risk of T. gondii increased with the number of 
siblings. 
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 Reykjavik 
OR (95% CI)* 
Uppsala 
OR (95% CI)* 
Tartu 
OR (95% CI)* 
All centre 
OR (95% CI)** 
Age (10 years) 1.06 (0.64-1.76) 1.67 (1.14-2.48) 0.91 (0.57-1.45) 1.23 (0.96-1.57)
Women 1.28 (0.65-2.51) 1.12 (0.67-1.88) 2.14 (1.14-4.00) 1.38 (0.995-
1.92) 
Ever smoker 1.25 (0.62-2.52) 1.28 (0.76-2.16) 1.15 (0.63-2.12) 1.13 (0.81-1.57)
One sibling 1.98 (0.79-4.98) 1.23 (0.68-2.22) 1.31 (0.70-2.45) 1.37 (0.94-2.00)
Two or more 
siblings 
2.46 (0.91-6.68) 2.12 (1.03-4.38) 2.31 (0.90-5.93) 2.18 (1.37-3.47)
Rural upbringing 1.01 (0.42-2.43) 0.87 (0.50-1.51) 1.09 (0.56-2.12) 0.99 (0.68-1.42)
Day care 3.72 (1.02-13.4) 1.63 (0.27-9.98) 0.67 (0.33-1.36) 0.99 (0.55-1.80)
Mothers age 0.95 (0.90-1.01) 0.98 (0.94-1.02) 1.07 (1.02-1.12) 1.00 (0.98-1.03)
Age when 
completing 
education 
1.03 (0.99-1.08) 0.99 (0.98-1.01) 1.00 (0.98-1.03) 1.00 (0.99-1.01)
Living in Uppsala - - - 3.16 (2.06-4.86)
Living in Tartu - - - 14.1 (8.79-22.5)
* Adjusted for all the variables in the table                                                                                
** Adjusted for centre and all the variables in the table 
Table 2. Age, sex, smoking and early life exposure variables and the risk of Toxoplasma 
gondi 
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Cat  exposure and the prevalence of T. gondii 
No significant association was found between cat keeping in childhood or at present and IgG 
antibodies against T. gondii  (Table 4). 
 Reykjavik 
OR (95% CI)* 
Uppsala 
OR (95% CI)* 
Tartu 
OR (95% CI)* 
All centre 
OR (95% CI)** 
Cat 1 year 0.51 (0.14-1.81) 1.59 (0.80-3.14) 1.40 (0.63-3.12) 1.22 (0.79-1.89)
Cat  age 1-4 years 0.81 (0.38-1.74) 1.45 (0.80-2.63) 1.40 (0.72-2.72) 1.21 (0.85-1.73)
Cat age 5-15 years 0.79 (0.39-1.58) 0.99 (0.56-1.74) 1.53 (0.83-2.81) 1.13 (0.80-1.58)
Cat now 2.09 (0.87-5.05) 1.01 (0.57-1.79) 1.21 (0.62-2.37) 1.17 (0.80-1.72)
* Adjusted for age, sex, smoking and early life exposure variable (table 2)                                                         
** Adjusted for centre and all the variables above 
 
Table 3. Cat ownership at different ages and the risk of T. gondi 
 
Association between T. gondii and respiratory symptoms, asthma and IgE-sensitisation 
T. gondii was significantly associated with nocturnal chest thightness and an increased risk of 
having at least two asthma related symptoms and was borderline significantly associated with 
decreased IgE-sensitisation (p=0.097) (Table 4). 
 
Association between T. gondii , lung function and systemic inflammation 
A week but statically significant association was found between T. gondii and HsCRP 
(r=0.07, p=0.02). No significant associations were found between T. gondii and FEV1 or 
FVC. 
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Table 4. Association between T. gondii and respiratory symptoms, asthma and IgE-sensitisation 
 Reykjavik p-value Uppsala p-value Tartu p-value Whole population 
 No Yes  No Yes  No Yes  OR* 
Wheeze 24.1 17.4 0.31 30.2 36.0 0.24 16.5 24.0 0.12 1.16 (0.83-1.63) 
Wheeze and breathlessness 10.2 6.5 0.43 20.2 28.1 0.08 9.1 12.8 0.35 1.35 (0.92-1.99) 
Wheeze without  a cold 16.4 13.0 0.56 20.4 24.6 0.13 11.7 9.2 0.29 1.25 (0.86-1.81) 
Nocturnal chest tightness 11.7 6.5 0.29 19.3 21.0 0.68 7.4 17.7 0.01 1.26 (0.85-1.86) 
Breathlessness at rest 6.4 2.2 0.25 8.7 13.4 0.15 7.4 13.3 0.12 1.30 (0.80-2.12) 
Breathlessness after effort  22.7 21.7 0.88 14.5 18.8 0.27 22.3 32.3 0.07 1.26 (0.86-2.21) 
Nocturnal breathlessness 2.2 0 0.31 12.6 15.9 0.36 7.4 13.9 0.09 1.37 (0.86-2.21) 
At least two asthma symptoms 24.4 21.7 0.68 31.2 39.1 0.12 15.7 30.4 0.004 1.40 (1.01-1.92) 
Nocturnal cough 22.3 15.2 0.27 38.9 32.7 0.24 20.7 23.4 0.58 0.81 (0.58-1.13) 
Morning cough 11.5 17.4 0.24 9.5 10.1 0.63 9.1 10.1 0.77 1.18 (0.73-1.91) 
Daytime cough 12.2 10.9 0.80 24.2 15.9 0.06 11.6 8.3 0.36 0.62 (0.40-0.96) 
Morning phlegm 16.2 19.6 0.56 15.1 14.4 0.86 15.7 18.4 0.56 1.18 (0.80-1.74) 
Daytime phlegm 9.5 10.9 0.76 14.8 14.9 0.97 11.6 10.1 0.70 0.95 (0.62-1.50) 
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Asthma 14.8 15.2 0.94 21.0 22.3 0.77 4.2 4.4 0.92 1.01 (0.66-1.55) 
IgE-sensitisation 17.0 17.4 0.95 40.2 28.3 0.02 25.0 21.7 0.51 0.75 (0.54-1.05) 
Adjusted for centre, age, sex, smoking and BMI 
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Discussion 
All analyses in our study were performed on a representative sample from the populations of 
the three countries in the age range 28-42 years. The samples were collected in the period 
1999-2001. The diagnostic sensitivity and the specificity of the T. gondii IgG ELISA method 
has been shown to be 96,8% and 100%, respectively (17). IgG antibodies appear within one to 
two weeks of infection with T. gondii, peak in six to eight weeks and then decline over the 
next two years but IgG antibodies remain detectable for life. Our methods should give an 
accurate estimate of the prevalence of  T. gondii in the three populations. 
The main finding in our study is a striking difference in prevalence of T. gondii  between the 
three countries, 9,8%, 23% and 54,9% respectively for Iceland, Sweden and Estonia. The risk 
of T. gondii infection was increased in participants that had been in day care before the age of 
3 years in Reykjavik. In the combined model for all countries the risk of T. gondii increased 
with the number of siblings. This suggests that soil exposure, which is greatest during the 
childhood years, may be one of the  mechanisms by which persons are exposed to T. gondii in 
the Nordic Baltic region.  The higher incidence in females than men in Estonia may also be 
related to soil exposure since women are more involved with child rearing than men.  
The risk of T. gondii infection increased with age in Sweden and this finding is compatible 
with cohort effect, with a higher risk for T. gondii infection in the past.  This suggests a 
transmission of T. gondii infection by meat since freezing of meat was formerly less common 
but freezing below 12 Cº kills T gondii cysts. Livestock rearing practices have also improved 
and have probably contributed to a decline in toxoplasmosis. Previous studies on T. gondii 
prevalence in Swedish women showed a declining prevalence from 34% in 1969 to 30% in 
1979 and 18% in 1987 (9) and this conforms to the age related increase in the present study.  
No significant associations were found in our study for having a cat in childhood or later in 
life, dog or rural or urban upbringing.  Previous studies on the risk of  T. gondii infection 
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associated with keeping cats have shown no association (21), negative association in 
Mexicans in USA (21) and no association in HIV infected adults (22). Cats excrete up to 10 
million oocysts per day but for only two weeks of their life, when they first acquire infection. 
Cats kept in urban environments should pose minimal risk of promoting T. gondii infection. 
The most likely explanation of the different prevalence between the countries is 
environmental exposure by ingesting infectious oocysts from contaminated soil or water.  
This route of infection is associated with socioeconomic development  and availability of 
clean running water which is a precondition of good  personal and household hygiene. 
Cooking practice and kitchen hygiene can be an important factor for transmission of  T. 
gondii particularly the contamination of cooked food with contaminated kitchen appliances. 
The high rating of Iceland and Sweden on the HDI scale is an indication of good standing in 
this respect. Estonia however is considerably lower on the HDI scale and was most likely in 
the medium HDI category before 1970 and with inferior hygienic sanitary standard compared 
to Iceland and Sweden.  
Another indirect indicator of hygienic standard is the prevalence of hepatitis A. The 
prevalence of anti-HAV IgG antibodies in Sweden was only 4% among a cohort born 
between 1948 and 1952 (23) which indicates a fairly high hygienic standard already during 
this period. In Iceland the prevalence of  anti-HAV IgG antibodies was 6% in a cohort born 
1950-59  (24) which also indicates a good hygienic standard. Nevertheless the prevalence of  
T. gondii infection in Sweden is 2,4 times higher than in Iceland and this raises the possibility 
of  other infectious routs in Sweden unrelated to hygiene.  However, the prevalence of  anti-
HAV IgG antibodies in Estonia in a cohort born around 1950 is ≈ 70% (unpublished 
measurements). 
Previous study in Iceland on T. gondii IgG antibodies in 139 women aged 17-32 years 
showed a prevalence of  4,7% (25). The blood samples were collected in 1979-80 for rubella 
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antibody measurements and an ELISA method was used for T. gondii IgG antibody 
measurements. This shows that the prevalence of  T. gondii infection in Iceland has remained 
low for two decades. There are some climatic differences between the countries related to 
different latitudes which are 59, 62 and 65 North for Estonia, Sweden and Iceland 
respectively. Warmer climate promotes T. gondii soil exposure (8) but the difference in 
temperature between the countries is however minimal  due to the North Atlantic Current 
around Iceland. 
The hypothesis, that disappearance of  T. gondii from the study populations would decrease 
the prevalence of  atopy and lung related allergy symptoms, is not supported by our study.  On 
the contrary T. gondii antibodies were significantly associated with an increased risk of 
having at least two asthma related symptoms. The hypothesis may depend more on the 
infectious burden from several pathogens rather than on single pathogens (14). Our study did 
not reveil any effect of  T. gondii on respiratory function. A weak but statistically significant 
association was found between T. gondii and elevated HsCRP  indicating  that T. gondii may 
to some extent be related to systemic inflammation. The association of T. gondii with an 
inflammatory parameter like Hs-CRP and asthma related symptoms may be connected but the 
precise mechanism is not clear. 
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